Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a blood pressure pill slow MS disability?

NCT ID NCT07765212

Disease control Sponsor: Eva M.M. Strijbis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This phase 2 trial tests whether indapamide, a common diuretic, can slow the worsening of walking ability in people with progressive multiple sclerosis (MS). Participants take one tablet daily for 12 months, with walking speed measured regularly. The study aims to see if the drug reduces the rate of disability progression in this hard-to-treat form of MS.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
indapamide, a diuretic medication taken as a daily tablet
What this could lead to
If successful, this could point toward a new treatment to slow disability progression in people with progressive forms of multiple sclerosis.
What could go wrong
This is an early-stage, open-label trial with no placebo group, so results may be inconclusive or not generalizable. Indapamide's safety and effectiveness for MS are unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent obtained * Aged between 18 and 65 years * Diagnosed with PPMS or SPMS, according to current diagnostic criteria * Screening Expanded Disability Status Scale score between 4.0 and 6.5 inclusive. * Screening T25FW (average of two trials) of 5 seconds or more for people with PPMS, or of 9 seconds or more for people with SPMS * Use of effective methods of contraception for women of childbearing potential. Exclusion Criteria: * Individuals with renal insufficiency and an eGFR below 30ml/min per 1.73 m2 * Individuals with a blood pressure below 110 mmHg systolic or 70 mmHg diastolic * Individuals with significant hepatic impairment (pre-existing or developing during the trial) * Individuals with clinically significant abnormal screening labs * Individuals with cardiac arrhythmia * Individuals with a prolonged QT interval: individuals with frequency corrected QT (QTc) intervals of more than 450ms (men) or 470ms (women) at the screening examination will not be included in the study, and participants with QTc intervals of greater than 500ms on any of the other ECG examinations throughout the study will be excluded from the study. * Individuals who are pregnant or currently breast-feeding * Individuals with an allergy or other intolerability to IND * Individuals who use Fampridine or 4-aminopyridine * Individuals who start Fampridine or 4-aminopyridine during the trial * Individuals who start Baclofen or Tizanidine during the trial * Individuals who increase the dose of Baclofen or Tizanidine during the trial * Individuals who receive treatment with Botulinum toxin in the leg muscles during the trial * Individuals who use siponimod, ocrelizumab, natalizumab or other disease-modifying treatment for RRMS * Individuals with recent gadolinium enhancement or new T2 lesions on brain/spinal cord MRI in the 6 months prior to inclusion * Concomitant use of corticosteroids

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic progressive multiple sclerosis multiple sclerosis primary progressive multiple sclerosis secondary progressive multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.